TBPH

Theravance Biopharma, Inc. (TBPH) ESG Analysis Analysis (2026)

Invetso Score: 6.9/10 — Balanced · Last Updated: 2026-08-01

Environmental

TBPH’s high R&D intensity versus peers supports lower-carbon innovation and process efficiency, but the available data do not show a clear environmental leadership gap.

The company’s capital allocation appears research-heavy rather than asset-intensive, which can limit direct operational emissions exposure relative to manufacturing peers.

No filing-based evidence provided here indicates material environmental controversies, yet the absence of disclosed emissions metrics prevents a stronger peer-relative score.

Environmental positioning is therefore mixed: innovation spending is supportive, but limited disclosure on climate and resource metrics keeps relative visibility below stronger peers.

Social

TBPH’s elevated R&D spend versus peers suggests sustained investment in medically relevant innovation, which can strengthen patient value creation and scientific credibility.

Stock-based compensation at a high revenue share may help retain specialized talent, although it can also signal heavier dilution pressure than better-aligned peers.

The company’s asset-light profile likely reduces workforce safety and community-impact complexity relative to industrial peers, supporting a cleaner social risk profile.

Overall social positioning is above average because innovation intensity and lower operational footprint outweigh compensation-related concerns that remain more visible than at top peers.

Governance

TBPH’s low debt-to-equity ratio indicates conservative balance-sheet governance relative to leveraged peers, reducing creditor pressure and financial fragility.

Negative net debt to EBITDA suggests liquidity strength, which generally supports governance flexibility and lowers refinancing risk versus more indebted comparators.

However, stock-based compensation near 19% of revenue is high versus disciplined peers, implying weaker capital-allocation efficiency and potential shareholder dilution concerns.

Governance is therefore solid but not leading, because balance-sheet prudence is offset by compensation intensity that remains less favorable than stronger peer practices.

Overall Score

TBPH’s ESG profile is moderately above average versus peers, led by strong social and balance-sheet characteristics, but limited environmental disclosure and high compensation intensity cap the score.

Score Driver: High R&D Intensity And Conservative Leverage Support Relative ESG Strength, While Limited Environmental Disclosure And Elevated Stock-Based Compensation Prevent A Stronger Rating.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Theravance Biopharma, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →